Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | JDQ443 |
Synonyms | |
Therapy Description |
JDQ443 inhibits KRAS G12C, which may lead to inhibition of downstream signaling and tumor progression (PMID: 35404998). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JDQ443 | JDQ 443|JDQ-443 | KRAS G12C inhibitor 32 | JDQ443 inhibits KRAS G12C, which may lead to inhibition of downstream signaling and tumor progression (PMID: 35404998). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04699188 | Phase Ib/II | JDQ443 JDQ443 + TNO155 JDQ443 + Tislelizumab + TNO155 JDQ443 + Tislelizumab | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
NCT05132075 | Phase III | JDQ443 Docetaxel | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02) | Recruiting | USA | ITA | GBR | ESP | CAN | 30 |
NCT05714891 | Phase II | JDQ443 | Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer | Recruiting | CAN | 0 |
NCT05445843 | Phase II | JDQ443 | Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression >= 1% and an STK11 Co-mutation. | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | 12 |